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Abstract
Introduction: There are numerous indications that either mannan-binding lectin (MBL) deficiency or its excessive activity
are associated with adverse pregnancy outcomes. High MBL concentrations and corresponding MBL2 genotypes were shown
to be associated with microvascular complications in type 1 diabetes. The aim of this study was to evaluate levels of MBL
and MBL-dependent activity of the lectin pathway (LP) of complement in the course of pregnancy in diabetic mothers, based
on genetic background. 
Materials and Methods: These parameters were determined in samples from healthy non-pregnant (control), diabetic non-
-pregnant, healthy pregnant, and pregnant diabetic women. 
Results: No significant differences in median MBL levels or LP activities were found in any study group compared to the con-
trol. However, statistically significant differences in MBL levels were noted during pregnancy between the 1st and 3rd trimesters
in both healthy controls and pregnant diabetics. With regard to LP values, similar trends were evident, but statistically signifi-
cant results were obtained only in the healthy pregnant group. When data analysis was confined to patients carrying the
A/A (wild-type) MBL2 genotype, an increase in MBL level during pregnancy (in both healthy and diabetic pregnant women)
was still observed. Similarly, LP activity increased during both healthy and diabetic pregnancies, significantly so for the former. 
Conclusions: Diabetes, an autoimmune disease, is a serious complication of pregnancy. Therefore, determination of MBL
status might be beneficial in identifying type 1 diabetic patients who are at increased risk of developing both vascular com-
plications and poor pregnancy outcomes.
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INTRODUCTION
The complement system is an important part of the
innate immune system. It can be activated via three dif-
ferent routes: the classical pathway, the alternative
pathway, and the lectin pathway (LP) (Turner 1996).
The LP performs a crucial role in the immune system by
recognizing pathogens through patterns of sugar moi-
eties displayed on their cell surfaces and neutralizing
them via an antibody-independent reaction cascade ini-
tiated by the binding of mannan-binding lectin (MBL)
or ficolins (Kilpatrick 2007). MBL plays an important
role in innate immunity by recognizing and initiating the
opsonization of microorganisms (Kilpatrick 2007;
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Turner and Hamvas 2000), activating complement inde-
pendently of the adaptive clonal immune system and
thus presenting an innate anti-microbial defense mech-
anism (Thiel et al. 2002). MBL is synthesized in the liver
and belongs to a family of proteins known as the col-
lectins, a group of C-type lectins possessing a collagen-
like helical domain. As a C-type lectin, this pattern
recognition molecule acts by binding to D-mannose, N-
-acetyl-D-glucosamine, and L-fucose residues presented
with the densities and orientations commonly found on
microbial surfaces, upon which it initiates complement
activation through association with serine proteases
(MBL-associated serine protease-1, -2, and -3) (Dahl et
al. 2001; Matsushita and Fujita 1992; Thiel et al. 1997;
Turner and Hamvas 2000). When bound to microorgan-
isms, the MBL complex mediates the activation of C4
and C2, generating the C3 convertase C4bC2b. The
C4/C2 cleaving activity of the MBL complex is shared by
the C1 complex of the classical pathway of complement
activation (Thiel et al. 2002). Emerging evidence indi-
cates that in some situations, MBL may cause activation
of the complement system and tissue injury by binding
to endothelial glycosylations (Hansen et al. 2003a). 
Single-nucleotide polymorphisms (SNPs) in exon 1
of the MBL2 gene are associated with individual MBL
serum levels as well as impaired MBL function.
Individuals with the A/A wild-type genotype have high-
er MBL serum concentrations, whereas individuals with
the A/O or O/O genotypes (where O is the collective
designation of the mutant dominant alleles D, B, and
C corresponding to mutations in codons 52, 54, and 57,
respectively) show lower MBL serum concentrations.
The presence of any of the minority alleles, when het-
erozygous, often results in a significant reduction in
serum MBL concentration, and when homozygous, in
an almost complete absence of the protein (Madsen et
al. 1995). Polymorphisms in the promoter and exon 1
untranslated region (H/L, Y/X, and P/Q at positions
–550, –221, and +4, respectively) influence the gene
expression level and thus the serum protein concentra-
tion. The highest MBL levels occur in association with
HYP/HYP and the lowest with LXP/LXP genotypes
(Madsen et al. 1995).
Pregnancy is associated with changes in the immune
system. There are indications that components of innate
immunity, such as MBL, are associated with pregnancy
outcome (Kilpatrick 2000), but the way in which innate
immunity changes during pregnancy has not been exten-
sively studied. There is some evidence that deficient
maternal MBL concentrations could act as a risk factor
for preterm birth and low birth weight (Annelss et al.
2004). However, Megia et al. (Megia et al. 2004)
demonstrated that pregnant women bearing the
G54D MBL allele have a greater risk of developing
GDM and having heavier infants. On the other hand,
high MBL concentrations as well as the corresponding
MBL2 genotypes were shown to be associated with
microvascular complications in type 1 diabetes
(Bouwman et al. 2005; Hansen et al. 2004).
In a preliminary report we demonstrated higher lev-
els of MBL in diabetic non-pregnant than in healthy
non-pregnant women (Pertynska et al. 2001). The aim
of the present study was to evaluate MBL levels and the
activity of the LP in the course of pregnancy in diabetic
mothers based on genetic background, i.e. MBL2 gene
exon 1 and promoter region SNPs.
MATERIALS AND METHODS
Fifteen pregnant (primigravidae) diabetic type 1
women (PD), patients of Diabetes Centre Research
Institute Polish Mother’s Memorial Hospital (RI
PMMH), demonstrating good glycemic control, were
first studied at 11–13 (n=15, group PD1) then at 34–36
(n=12, group PD3) weeks of gestation (according to the
date of the last menstrual period confirmed by ultra-
sound). Fourteen non-pregnant type 1 diabetic women
(D) of the Outpatients Diabetes Center of the RI
PMMH, 15 healthy non-diabetic nulliparous women
(C), and 16 healthy pregnant (primigravidae) women
(P) between 11–13 (n=16, group P1) and again between
34–36 (n=10, group P3) weeks of gestation matched for
age and parity were also studied. All of the patients were
between 20–30 years of age (mean: 23.6 years); all the
pregnant women were primigravidae. No patient had
clinical signs of active infection at the time of the study
and for at least 4 weeks prior to it. All the diabetic
women had fasting glucose levels <110 mg/dl.
Glycosylated hemoglobin (HbA1C) concentration was
measured using an Integra HbA1C 150 kit manufac-
tured by Roche. Fasting blood samples of 5 ml were
obtained from an antecubital vein between 8 and 9 AM.
Serum samples were obtained from blood taken into
Vacutainer tubes. Agreement of the local ethics com-
mittee as well as informed consent from all the investi-
gated patients had been obtained.
MBL level and LP activity determination
MBL concentration in human serum and LP activity
were determined essentially as described by Cedzynski
et al. (Cedzynski et al. 2004). Briefly, diluted serum was
incubated on mannan-coated plates and bound MBL
was detected using murine anti-human MBL (clone131-
1; AntibodyShop, Denmark), peroxidase-conjugated
rabbit anti-mouse immunoglobulin (Sigma, USA), and
2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic) acid
(Sigma, USA). The MBL-MASP-2 complex-dependent
LP of complement activity (C4b deposition) was also
measured by ELISA as previously described according
to the method originally described by Petersen et al.
(Petersen et al. 2001) in our modification (Cedzynski et
al. 2004). Briefly, serum serially diluted in a high-ionic-
-strength buffer (Petersen et al. 2001) was incubated on
mannan-coated plates. Then complement component
C4 (Sigma, USA) was added and, after incubation and
washing steps, the primary antibody (rabbit anti-human
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C4 serum from Sigma, USA) was added, followed by the
secondary antibody (peroxidase conjugated goat anti-
-rabbit Ig from DAKO, Denmark). 2,2’-azino-bis(3-eth-
ylbenz-thiazoline-6-sulfonic) acid (ABTS, Sigma, USA)
was employed as the substrate for peroxidase. The
serum of a healthy blood donor of HYPA/HYPA geno-
type containing 2000 ng/ml MBL was used as a standard
for which LP activity was arbitrarily determined as 1000
mU/ml.
MBL2 genotyping
DNA was extracted from the blood samples accord-
ing to the GTC method (Chomczynski 1993). Exon 1
MBL2 gene was amplified by PCR (685 bp) using the
primers 5′ AGTCGACCCAGATTGTAGGACAGAG
3′ and 5′ AGTTGTTGTTCTCCTGTCCAG 3′ (Madsen
et al. 1995). The PCR products were digested by BanI
and MboII restriction enzymes and separated on a 6%
polyacrylamide gel. 
The D allele was detected by the RFLP method per-
formed on the PCR products of 125 bp using the
primers 5′ CATCAACGGCTTCCCAGGCAAA-
GACGCG 3′ and 5′ AGGATCCAGGCAGTTTC-
CTCGGAAGG 3′ (Madsen et al. 1995). The PCR prod-
uct was digested by MluI and HhaI restriction enzymes
and electrophoresed on a 6% polyacrylamide gel in
TAE buffer. 
The cis-trans promoter/exon 1 untranslated region
variants H, L, X, Y, P, and Q relative to the structural vari-
ants A, B, C, and D were determined by PCR using the
primers 5′ GGAGGCTTAGACCTATGGGGCTAGG 3′
and 5′ GGGACATGGTCCTCACCTTGGTG 3′
(Madsen et al. 1995). The appropriate PCR products of
866 bp were separated on Wizard columns (Promega,
USA) and sequenced by the dideoxy chain termination
method (Epicentre Technologies, USA) starting from the
primers specific for H/L: 5′ CCAACGTAGTAA-
GAAATTTCC 3′, X/Y: 5′ GGCATAAGCCAGCTG-
GCAATGC 3′, and P/Q: 5′ GGGATGGGTCATC-
TATTTCTATATAGCC 3` (Madsen et al. 1995). 
Statistics
The Statistica 8.0 (StatSoft Poland) software pack-
age was used for data management and statistical calcu-
lations. Results are shown as medians. For statistical
evaluation the Mann-Whitney U-test or Wilcoxon test
were implemented where appropriate. A p value of
<0.05 was considered as indicative of a significant dif-
ference.
RESULTS
MBL concentrations and LP activity were determined
in serum samples from 15 healthy non-pregnant (control
group C), 14 non-pregnant diabetic (D), 16 healthy preg-
nant women in the first trimester (P1), and 15 pregnant
diabetic women in the first trimester (PD1). No signifi-
cant differences in median MBL level were found in any
studied group (D, P1, or PD1) compared to the control
(Table 1). Similarly, median LP, reflecting the ability to
deposit C4b, did not differ significantly among the
healthy pregnant, pregnant diabetic, or non-pregnant dia-
betic patients and healthy non-pregnant nulliparous con-
trols (Table 2). Two persons in group P, three in D, two
in CD, and none in C were found to be MBL deficient
(concentrations not exceeding 100 ng/ml). 
Furthermore, MBL concentrations and LP activity
were determined in serum samples from 13 pregnant
diabetic women in the third trimester (PD3) and 10
healthy pregnant women in the third trimester (P3). The
numbers in the third trimester groups differ from the
first trimester due to two miscarriages in the diabetic
pregnant group and the fact that six of the healthy preg-
nant patients either decided to deliver in another city
(n=5) or did not appear for blood collection (n=1).
Again, no significant differences in median MBL level
were found with any group studied (D, P3, or PD3)
compared to the control. Similarly, median LP did not
differ significantly among the healthy pregnant, preg-
nant diabetic, or non-pregnant diabetic patients and the
Table 1. MBL concentration [ng/ml] in sera of healthy non-
-pregnant (C), non-pregnant diabetic (D), healthy pregnant
(P), and diabetic pregnant (PD) women in the 1st and 3rd
trimesters
Group Median Mean Range p
C 1807 2008 140–5819
D 1114 2067 21–6601 0.73a
0.85b
P1 2118 2332 88–5593 0.65a
0.69b
PD1 1542 2168 34–5895 0.97a
P3 2932 2934 115–6074 0.005c
PD3 1877 2603 33–6236 0.003b
a vs. C, b vs. PD1, c vs. P1
Table 2. LP activity [mU/ml] in sera of healthy non-pregnant
(C), non-pregnant diabetic (D), healthy pregnant (P), and
diabetic pregnant (PD) women in the 1st and 3rd trimesters
Group Median Mean Range p
C 591 643 96–2242
D 565 733 27–1972 0.66a
0.73b
P1 747 745 72–1373 0.45a
0.9b
PD1 834 933 40–3229 0.51a
P3 1257 1049 38–1755 0.013c
PD3 1242 1192 63–2954 0.06b
a vs. C, b vs. PD1, c vs. P1
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healthy non-pregnant nulliparous women. However,
statistically significant differences in MBL levels
between the first and third trimesters were noted in both
the healthy pregnant (P1 vs. P3, p=0.005) and the preg-
nant diabetic groups (PD1 vs. PD3, p=0.003) (Table 1).
With regard to LP values, a statistically significant dif-
ference in LP activity between the first and third
trimesters was noted for the healthy pregnant group (P1
vs. P3, p=0.013). A similar trend was evident in the
pregnant diabetic group, but it did not reach statistical
significance (p=0.06) (Table 2).
We also determined MBL2 genotypes, and then
serum MBL levels, and LP activities in the subjects who
possessed the A/A genotype only. Similarly, we found an
increase in MBL level in both healthy controls and dia-
betic patients during the course of pregnancy. LP activ-
ity increased significantly in the course of healthy preg-
nancies, but only a weak trend was apparent in the dia-
betic patients (p=0.18; Table 3). It should be mentioned
that, as expected, the distribution of O variants was sim-
ilar in the studied groups: among 16 healthy pregnant
women, 2 were A/O heterozygotes (LYPA/LYPB and
LXPA/HYPD) and 1 had the homozygous LYPB/LYPB
genotype; among 13 pregnant diabetic patients, 5 had
A/B genotypes (2 LYQA/LYPB, 2 LXPA/LYPB, and 1
HYPA/LYPB); 6 of 15 healthy non-pregnant women
carried the B (3 HYPA/LYPB and 2 LXPA/LYPB) or C
(HYPA/LYQC) variant; and among 14 diabetic non-
-pregnant patients, 5 had A/B heterozygotes (2
HYPA/LYPB and 3 LXPA/LYPB) and 1 had variant
LYPB/HYPD heterozygote. All totally MBL-deficient
individuals (concentrations <100 ng/ml) had the O/O or
LXPA/O genotypes.
The glycosylated hemoglobin (HbA1C) results are
shown in Table 4. As expected, significant differences
were noted in the D and PD groups compared to the
control. No differences were found between groups
D and PD, which indicates good glycemic control of the
pregnant diabetic women, with medians of 7.0 mg% for
group D, 7.0 mg% for PD1, and 6.4 mg% for PD3. The
statistical analysis did not reveal any significant correla-
tion between MBL levels or LP activities and HbA1C in
the studied diabetic groups (data not shown).
The glucose levels did not differ significantly
between diabetic pregnant women bearing the A/A and
A/B genotypes. In the first trimester, median values
were 183 mg% (genotype A/A) and 107 mg% (A/B,
p=0.09). In the third trimester the levels were 147 mg%
and 112 mg%, respectively (p=0.09).
DISCUSSION
The serum level of MBL is genetically determined to
a major extent (Husby et al. 2002), although non-genet-
ic influences are also relevant (Sorensen et al. 2006) and
it is well known that individual concentrations within the
same genotype may vary significantly. Hansen et al.
(Hansen et al. 2004) showed that the higher concentra-
tions of MBL among diabetic patients were not
explained by genetic predisposition because they found
identical genotype distributions in patients and healthy
control subjects. In early-onset diabetic patients, MBL
serum concentration and activity were increased upon
manifestation independently of genetic predisposition
to high MBL production, indicating a possible role in
the immunopathogenesis of type 1 diabetes in addition
to adaptive islet autoimmunity (Bouwman et al. 2005).
Tsutsumi et al. suggested that possession of the minori-
Table 3. Comparison between MBL [ng/ml] and LP [mU/ml] levels in patients with A/A genotype: healthy non-pregnant (C), non-
-pregnant diabetic (D), healthy pregnant (P, 1st and 3rd trimesters), and diabetic pregnant (PD, 1st and 3rd trimesters)
Group MBL [ng/ml] Statistical LP [mU/ml] Statistical 
median mean significance median mean significance
C 2420 3005 757 909
D 4057 3307 1238 1107
P1 2848 3324 813 996
P3 3244 3540 p=0.012a 1382 1272 p=0.017a
PD1 3163 3250 1328 1446
PD3 4008 4419 p=0.018b 1598 1773 p=0.18b
a vs. P1, b vs. PD1
Table 4. Concentration of glycated hemoglobin (HbA1C) [%]
in sera of healthy non-pregnant (C), non-pregnant diabetic
(D), healthy pregnant (P), and diabetic pregnant (PD)
women in the course of pregnancy (1st and 3rd trimesters)
Group Median Mean p
C 5.2 5.2
D 7.0 7.6 <0.00001a
0.25b
P1 5.2 5.3 0.46a
0.00002b
PD1 7.0 7.0 <0.00001a
P3 5.2 5.3 0.44c
PD3 6.4 6.3 0.084b
a vs. C,b vs. PD1, c vs. P1
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ty allele of the MBL2 gene may be a minor risk factor for
type 1 diabetes (Tsutsumi et al. 2003). In a preliminary
study in 2001 we demonstrated higher levels of MBL in
diabetic non-pregnant compared to healthy non-preg-
nant women (Pertynska et al. 2001).
Hansen et al. demonstrated that circulating MBL
concentrations were significantly elevated in patients
with diabetes type 1 and suggested a possible role of
MBL in the pathogenesis of renovascular complications
in diabetes (Hansen et al 2003a). In a study by Hovind
et al. (Hovind et al. 2005), high levels of MBL early in
the course of type 1 diabetes were significantly associat-
ed with a higher risk of developing persistent micro- or
macroalbuminuria. This finding again suggests that
complement activation initiated by MBL is likely to be
a contributing factor in the pathogenesis of diabetic
microangiopathy (Hovind et al. 2005). In diabetic
patients, treatment with insulin could play a very impor-
tant role in regard to MBL level. Hansen et al. (Hansen
et al. 2003b) showed that insulin has a significant sup-
pressive effect on circulating MBL levels in critically ill
patients. To explain the difference in MBL level
between healthy and diabetic patients they suggested
that in patients with diabetes type 1, treatment with
injectable insulin preparations is associated with sys-
temic hyperinsulinemia and hepatic portal hypoinsu-
linemia. As MBL is a protein synthesized mainly in the
liver, in such a case hepatic MBL expression may be
chronically unregulated in these patients because of the
low portal insulin concentration (Hansen et al. 2003a).
In the present study we did not notice any statistically
significant difference in the levels of MBL or LP activi-
ty between the corresponding groups studied. This,
however, could be due to the good metabolic control of
our diabetic and pregnant diabetic patients (median
HbA1C for groups D: 7.0 mg%, PD1: 7.0 mg%, PD3:
6.4 mg%). Although we noted increasing levels of MBL
in the course of diabetic pregnancy, only two of patients
had retinopathy, in both cases as a preexisting condition.
Pregnancy is associated with changes in the immune
system. There are indications that components of innate
immunity, such as MBL, may influence pregnancy out-
come. Although this would suggest that pregnancy also
involves adaptations in innate immunity, there are only
a few studies addressing this issue. In a Dutch study,
MBL concentrations increased by up to 140% during
pregnancy. This increase was already present at the 12th
week of pregnancy and was most pronounced in the
high-production A/A genotype. However, the effect of
the promoter polymorphisms could also be observed
(van de Geijn et al. 2007). On the other hand, Kilpatrick
showed that this increase in MBL concentration may
not always occur in the first trimester (Kilpatrick 2000).
He noted that in eight women with a history of recurrent
spontaneous miscarriage, no increase in MBL could be
observed during the first trimester of pregnancy. This
might suggest that a rise in MBL level in early pregnan-
cy is important for proper development. Low maternal
serum MBL levels showed a negative impact on preg-
nancy outcome in women with unexplained recurrent
spontaneous abortion. Patients with MBL levels of ≤100
ng/ml had a higher abortion rate than patients with nor-
mal MBL concentrations (p<0.05). The median birth
weight of children who were born at term to women with
recurrent spontaneous abortion was 287 g less in the
women with MBL levels of ≤100 ng/ml than in the
women with normal concentrations (p=0.04) (Kruse et
al. 2002).
In our preliminary report (Pertynska et al. 2001) we
did not notice any significant increase in MBL concen-
tration in early pregnancy. Similarly, in the present
study we did not observe any significant rise in MBL
level or LP activity among women between 11 and 13
weeks of pregnancy compared to the corresponding
control groups of non-pregnant women. However, we
showed a significant increase in MBL levels in a healthy
and, for the first time, a diabetic pregnant group in the
course of pregnancy (when the values determined dur-
ing the first and third trimesters were compared).
Moreover, we showed that LP activity, reflecting the
ability to deposit C4b, increased in the course of healthy
pregnancy and a similar trend was noticed in the diabet-
ic pregnant group (p=0.06). When data from patients
carrying A/A genotypes were compared to avoid statisti-
cal noise caused by MBL deficiency, an increase in MBL
level in the healthy and diabetic pregnant groups in the
course of pregnancy was again observed. Similarly, LP
activity increased significantly in the course of healthy,
but not diabetic pregnancy.
Megia et al. showed that the mean birth weight of
babies of GDM mothers carrying the codon 54 mutation
(B allele) was significantly higher than in a group of
women homozygous for the wild-type gene (3326.4±
546.9 vs. 3087.5±395.5 g, p<0.05) (Megia et al. 2004).
We observed a similar trend in type 1 diabetic mothers
(4020±336.1 vs. 3882.9±696.9 g). The difference was
not significant; however, it should be remembered that
the number of samples studied was very small. Megia et
al. analyzed the basal glucose levels in the tolerance test
in the GDM group. Women bearing the mutated allele
had higher mean glucose levels than those homozygous
for the wild-type gene (Megia et al. 2004). We looked at
the glucose levels obtained at the day of blood collection
for the purposes of our study in the diabetic pregnant
women. We did not find any statistical difference
between women bearing the A/A and A/B genotypes. 
There is no clear evidence concerning the purpose of
increased MBL levels in pregnancy. It is well known that
pregnancy is a state of powerful immune suppression,
which allows the fetus to survive despite being a poten-
tial target for the maternal immune system. Multiple
overlapping mechanisms exist to prevent maternal allo-
genic immune responses towards the fetus while main-
taining the capacity to mount a defense against infec-
tious organisms (Koch and Platt 2003). Since adaptive
immunity declines during pregnancy, the mother is more
susceptible to infections, both viral and (intracellular)
bacterial, such as Neisseria and Mycoplasma (Beagley
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and Gockel 2003). Another factor that might contribute
to increased susceptibility to viral infection is proges-
terone (Kaushic et al. 2003). One could hypothesize that
since the balance of Th1/Th2 is crucial for pregnancy
development and term delivery, then the increasing level
of MBL in the course of pregnancy may be necessary to
compensate for reduced T-cell function during the state
of reduced adaptive immunity (van de Geijn et al. 2007;
Raghupathy 1997; Szekeres-Bartho et al. 1997). 
Recently, van de Geijn et al. (van de Geijn et al.
2008) found an association between maternal high MBL
level-associated genotypes and premature birth, sug-
gesting that during pregnancy, MBL-associated inflam-
mation caused by higher MBL activity may contribute to
earlier delivery. Furthermore, this finding might explain
why so many individuals are MBL deficient in the gen-
eral population (van de Geijn et al. 2008). Moreover,
Swierzko et al. recently reported that the high serum
MBL-conferring A/A genotypes in neonates are associ-
ated with prematurity. Consistent with that, low (defi-
ciency) MBL levels were underrepresented among pre-
mature babies (Swierzko et al. 2009). It is very probable
that although MBL is protective when a pathogen is to
be eliminated by an inflammatory complement-depen-
dent response, persistent activation may in some cases
lead to an excessive response (Ameglio et al. 2007;
Swierzko et al. 2009). Since, as mentioned, intrauterine
infections are one of the main reasons for premature
deliveries, it is possible that, however rarely, higher
MBL levels might be disadvantageous. Indeed, these
data add to the ever-increasing number of contexts in
which high MBL seems to be harmful (Berger et al.
2007; Bilgin et al. 2008; Fiane et al. 2003; Hansen et al.
2006; Hellemann et al. 2007; Kilpatrick 2007;
Schlapbach et al. 2007). On the other hand, there are
numerous reports showing an association between MBL
deficiency in mothers or babies with prematurity or pre-
natal/perinatal infections (Annells et al. 2004; De
Benedetti et al. 2007; Bodamer et al. 2006; Frakking et
al. 2007). 
Type 1 diabetes, like rheumatoid arthritis, is an
autoimmune disease and symptoms of rheumatoid
arthritis sometimes improve during pregnancy.
Increased concentration of MBL in the course of preg-
nancy might affect pregnancy outcome. Thus, probably,
both total MBL deficiency and high level/activity during
pregnancy complicated by diabetes might be dangerous
for the fetus and/or mother. 
We realize that the small numbers of patients in the
study groups constitute a major limitation. It reflects,
however, the very strict manner of their qualification.
First, in the non-pregnant diabetic group all of the
selected patients were nulliparous. In practice, in a hos-
pital setting it is extremely difficult to obtain blood sam-
ples from women with diabetes who had never been
pregnant before. It is only possible in centers providing
special care for women with diabetes preparing for preg-
nancy. In 2007 the Society of Obstetricians and
Gynecologists of Canada published guidelines for the
management of diabetic pregnancy. It stated (just as in
the St. Vincent declaration of 1989) that women with
diabetes should be offered pre-conception counseling
with a multidisciplinary team to optimize general health
and glycemic control and to review the risks of congeni-
tal anomalies. Moreover, they emphasized that preg-
nancy in women with diabetes should be planned.
Unfortunately, the awareness of such care in the diabet-
ic population is still low and therefore most patients in
our Diabetes Center of the RI PMMH (£ódŸ, Poland),
are women who have already experienced miscarriage,
lost a baby, or delivered a macrosomic baby or a baby
with congenital malformations. Primigravidae were
selected for our study group of pregnant diabetic
women, which makes it clear why there were only 15 of
them. Moreover, all of the patients were between 20–30
years of age. Again, in practice it is extremely difficult to
find young women (mean age: 23.6 years) suffering from
diabetes who are aware that they should report for preg-
nancy planning. 
We believe that our study is the very first to show
MBL/LP fluctuations in the course of pregnancy of dia-
betic primigravidae and provides a unique opportunity
to observe these changes in a very strictly selected group
of patients. Increasing levels of MBL (and other innate
immunity factors) in the course of pregnancy may be
necessary to compensate for reduced T-cell function
during a state of reduced adaptive immunity. Higher
levels of MBL and LP could indicate a shift from adap-
tive to innate immunity.
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